Viral Hepatitis

SAN ANTONIO — In this exclusive video from the National Liver Conference 2019, Robert Gish, MD, an adjunct professor at the University of Nevada Reno School of Medicine, provides an overview of a presentation on hepatitis B that focused on which patients benefit the most from treatment.

From 2013 through 2016, an estimated 2.4 million adults in the United States had a current hepatitis C virus infection. A study published in The American Journal of Public Health reported that the infection rate increased more than twofold between 2004 and 2014 as a result of the opioid epidemic.

From 2013 through 2016, an estimated 2.4 million adults in the United States had a current hepatitis C virus infection. A study published in The American Journal of Public Health reported that the infection rate increased more than twofold between 2004 and 2014 as a result of the opioid epidemic.

Results from an estimation model revealed that Australia will marginally miss both its local targets and the WHO’s global targets for eliminating chronic hepatitis B.

By 2019, hepatitis C-seronegative patients who underwent kidney transplantation mostly received HCV-viremic donor organs, which demonstrated the same level of function as uninfected kidneys over the course of 1-year follow-up.

In a follow-up analysis of participants in clinical trials, researchers found that patient-reported outcome scores increased in patients who achieved sustained virologic response after treatment for hepatitis C, whereas scores decreased in those who did not.

Most patients with hepatitis C in Africa have genotypes outside of the common and easily cured genotype 1a and genotype 1b, which has led to a suboptimal rate of sustained virologic response.

For Eric Lawitz, MD, research is its own reward.

Douglas T. Dieterich, MD, director of the Institute for Liver Medicine at Mount Sinai Health Systems, and professor of medicine at the Icahn School of Medicine at Mount Sinai in New York, brings a unique perspective with him to work every day.

When Vincent Lo Re III, MD, MSCE, first entered the clinical epidemiology field, he did not know the rewarding career path on which it would lead him several years later.